October 24, 2016 1:25 AM ET


Company Overview of Capsugel Inc.

Company Overview

Capsugel Inc. develops dosage forms and solutions for the healthcare industry around the world. It offers gelatin, alternate polymer, and liquid-filled capsules; hard gelatin, sprinkle, plus HPMC, fish gelatin, pearlescent, over-encapsulation, pre-clinical, liquid, soft gelatin, acid-resistant capsules; gelcaps; capsule in capsule technology products; and solid lipid pellet technology products. The company also provides precision powder micro-dosing systems, CFS liquid filling and sealing machines, profill manual capsule filling machines, and commercial scale capsule filling machines. The company develops drug delivery technology platform, enTRinsic, that offers enteric protection without th...

412 Mount Kemble Avenue

Suite 200-C

Morristown, NJ 07960

United States

Founded in 1963



Key Executives for Capsugel Inc.

Chief Executive Officer and President
Chief Financial Officer
Age: 52
Chief Marketing Officer and Senior Vice President
Senior Vice President of Research and Development
Senior Director of Corporate Communications
Compensation as of Fiscal Year 2016.

Capsugel Inc. Key Developments

Investors Reportedly Eyes To Acquire Capsugel

Capsugel Inc. is preparing to explore a sale or initial public offering (IPO) that could value it at more than $5 billion including debt, according to people familiar with the matter. Several companies have reached out to Capsugel in recent weeks to express interest in an acquisition, including 3M Company (NYSE:MMM), Danaher Corp. (NYSE:DHR), Becton, Dickinson and Company (NYSE:BDX), Thermo Fisher Scientific, Inc. (NYSE:TMO), Bayer AG (DB:BAYN) and Catalent, Inc. (NYSE:CTLT), the people said this week. As a result, Capsugel's owner, KKR & Co. L.P. (NYSE:KKR) is preparing to run a sale process for the company later this year, and also explore the possibility of an IPO as an alternative to an outright sale, the people said. The sources asked not to be identified because the sale process is confidential. KKR and 3M declined to comment, while representatives of Capsugel, Danaher, Becton-Dickinson, Thermo Fisher, Bayer and Catalent did not respond to requests for comment.

Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

Capsugel and Pulmatrix, Inc. (Pulmatrix) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE™-based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners. Capsugel will combine its spray drying process development, scale-up expertise and commercial manufacturing capabilities at its Bend Research facility in Bend, Ore. with Pulmatrix's iSPERSE (inhaled small particles easily respirable and emitted) technology. Pulmatrix's iSPERSE dry powder technology is a small, dense and dispersible engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility and flow-rate independence. Several products leveraging the iSPERSE platform are in development, including a lead clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease (COPD), an inhaled anti-fungal (PUR1900) for cystic fibrosis (CF) and a pipeline of products for use in the treatment of rare pulmonary diseases, CF and idiopathic pulmonary fibrosis.

Capsugel Introduces enTRinsic Drug Delivery Technology Platform

Capsugel has launched its enTRinsic drug delivery technology platform, which offers enteric protection without the requirement of functional coatings. The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract. It allows oral delivery of several compounds, including vaccines, proteins and peptides, using pharmaceutically approved enteric polymers. The technology is now available worldwide for customer projects after the completion of a lead-user customer-collaboration program, which was undertaken in 18 months. The enTRinsic technology further expands Capsugel's range of modified and targeted release solutions, and the company's biotherapeutic formulation offering.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

December 14, 2015
100% in Xcelience, LLC and Remaining Stake in PowderSize, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Capsugel Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.